DAY 101-001, A Phase 2 Study of the Oral pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Mutated Low Grade Glioma

Clinical Trial Grant

Duke Scholars

Principal Investigator Daniel Bryce Landi Pediatrics, Hematology-Oncology

Administered By

Duke Cancer Institute

Awarded By

DOT Therapeutics-1

Start Date

April 26, 2021

End Date

April 30, 2026

Administered By

Duke Cancer Institute

Awarded By

DOT Therapeutics-1

Start Date

April 26, 2021

End Date

April 30, 2026